Serpin Pharma, LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.serpinpharma.com
SP16 as a Therapeutic for COVID-19 Induced ARDS
Phase 1
Terminated
- Conditions
- SARS CoV 2 InfectionPneumonia
- Interventions
- Drug: SP16 (12 mg)Drug: SP16 (6mg)Other: Placebo
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Serpin Pharma, LLC
- Target Recruit Count
- 2
- Registration Number
- NCT05135624
- Locations
- 🇺🇸
UVA Health Center, Charlottesville, Virginia, United States
SP16 Inflammatory Response Inhibition Trial
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Serpin Pharma, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT04225533
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
SP16 SERPIN-like Peptide Administration in Healthy Individuals
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Serpin Pharma, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03651089
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath